No profile data available.
Inhibikase Therapeutics, Inc. (IKT) is a healthcare company in the brain and nerve treatment drugs industry, based in Atlanta, United States, with about 15 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$48.26 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $183.11 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Inhibikase Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$183.11 million as of December 4, 2025.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Alector, Inc. (ALEC), Entrada Therapeutics, Inc. (TRDA), Alpha Cognition Inc. (ACOG), PepGen Inc. (PEPG).